Clinical trials: TURBT
Urinary Bladder Tumor
Clinical Trial Using Bipolar Technology for Transurethral Resection of Bladder Tumor
Bladder cancer is a common urological malignant disease. Patients with bladder cancer will first be managed with transurethral resection (TUR) of bladder tumor.
- Trial name
- NCT01581723
- Testing
- Monopolar diathermy, Bipolar diathermy
- Where
- 2 sites in Hong Kong
- Volunteers
- 150 people
- Sponsor
- Chinese University of Hong Kong
Bladder Tumor (TURBT)
Holmium Laser En-Bloc Resection Versus Conventional Transurethral Resection of Bladder Tumors for Treatment of Non-muscle- Invasive Bladder Cancer
This study is a prospective randomized controlled trial comparing holmium laser en-bloc resection of bladder tumor (HoLERBT) with conventional transurethral resection of bladder tumor (cTURBT) in patients with suspected…
- Trial name
- NCT07534631
- Testing
- Holmium Laser En-Bloc Resection of Bladder Tumor, Conventional Transurethral Resection of Bladder Tumor
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Beni-Suef University
Bladder Tumors, Spinal Anesthesia
Magnesium vs. Dexmedetomidine in TURBT Under Spinal Anesthesia
This randomized controlled trial evaluated the effects of intraoperative intravenous magnesium sulfate versus dexmedetomidine on postoperative pain, analgesic consumption, hemodynamic stability, and respiratory function in…
- Conditions
- Bladder Tumors, Spinal Anesthesia, Postoperative Pain, Magnesium Sulfate
- Trial name
- TURBT (NCT07445451)
- Testing
- magnesium sulfate, Dexmedetomidine, Normal Saline
- Where
- Turkey (Türkiye)
- Volunteers
- 93 people
- Sponsor
- Dr. Lutfi Kirdar Kartal Training and Research Hospital
Urinary Bladder Neoplasm
Holmium Versus Bipolar en Bloc Transurethral Resection of Urothelium Tumor of the Urinary Bladder
En bloc resection of bladder tumors (ERBT) may improve staging quality and perioperative morbidity and influence tumour recurrence
- Trial name
- NCT04576286
- Testing
- Holmium versus Bipolar en bloc transurethral resection
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Ain Shams University
Non-Muscle-Invasive Bladder Cancer, BCG-Unresponsive Bladder Cancer
Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
This prospective, randomized, open-label, phase II clinical trial compares two sequential intravesical chemotherapy regimens in patients with bacillus Calmette-Guérin (BCG)-unresponsive high-grade non-muscle-invasive bladder…
- Trial name
- GEMDOC-MMC (NCT07747740)
- Testing
- Gemcitabin, Docetaxel, Mitomicin C
- Where
- Russia
- Volunteers
- 228 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Transurethral Resection of Bladder Tumor, Transurethral Resection of the Prostate (TURP)
Effect of Cyclic Sighing Breathing Exercise on CRBD, Pain, and Sleep Quality in Patients Undergoing TUR
Transurethral resection (TUR) is a common minimally invasive surgical procedure for lower urinary tract diseases. However, postoperative urinary catheterization often causes catheter-related bladder discomfort (CRBD) and pain due…
- Conditions
- Transurethral Resection of Bladder Tumor, Transurethral Resection of the Prostate (TURP), Transurethral Resection of the Bladder
- Trial name
- NCT07843602
- Testing
- Cyclic Sighing Breathing Exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 76 people
- Sponsor
- Mersin University
Urinary Bladder Neoplasms
The Bladder Instillation Comparison Study
To compare the efficacy of Mitomycin C vs. Gemcitabine vs. no adjuvant treatment as a single intraoperative instillation in preventing recurrence of bladder cancer.
- Trial name
- BIC (NCT02695771)
- Testing
- Mitomycin C, Gemcitabine
- Where
- 3 sites in United States
- Volunteers
- 101 people
- Sponsor
- Corewell Health West
Non Muscle Invasive Bladder Cancer
The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection
The goal of this clinical trial is to evaluate the efficacy of using a urine biomarker test to guide the decision-making process regarding the necessity of reTURBT in NMIBC patients.
- Trial name
- NCT06287541
- Testing
- Urine biomarker -Guided without reTURBT
- Where
- China
- Volunteers
- 428 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
NMIBC
A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.
This prospective, multicenter, single-arm phase II trial aims to evaluate the clinical efficacy and safety of the combination therapy of Disitamab Vedotin with Tislelizumab and a second transurethral resection for the treatment…
- Trial name
- NCT06630871
- Testing
- Distitamab Vedotin in combination with Tislelizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fujian Medical University Union Hospital
Bladder Cancer
AI-Guided TURBT for Bladder Cancer
This prospective, randomized, controlled, single-center study evaluates whether an AI navigation planning system used during Transurethral Resection of Bladder Tumor (TURBT) can improve recurrence-free survival in patients with…
- Trial name
- AITURBT (NCT07727343)
- Testing
- AI Navigation Planning System
- Volunteers
- 170 people
- Sponsor
- Fudan University
Bladder Cancer, Gemcitabine and Cisplatin Chemotherapy
Transurethral Resection of Bladder Tumor (TURBT) Combined With Adjuvant Intravenous GC Chemotherapy for Non-muscle-invasive Bladder Cancer
It is still a challenge for urologic surgeon to prevent the post transurethral resection of bladder tumor (TURBT) recurrence of moderate-high risk non-muscle invasive bladder tumor.
- Conditions
- Bladder Cancer, Gemcitabine and Cisplatin Chemotherapy, Epirubicin Instillation, Recurrence
- Trial name
- NCT02716961
- Testing
- Gemcitabine, cisplatin
- Where
- China
- Volunteers
- 208 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
TURBT
Application of Pericapsular Nerve Group (PENG) Block
This study aims to determine the efficacy and safety of the Pericapsular Nerve Group (PENG) block in preventing obturator nerve reflex during transurethral resection of bladder tumors.
- Trial name
- NCT07078773
- Testing
- peng block, obturator nerve block
- Where
- China
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Hemorrhage
Safety and Efficacy of Intravenous Tranexamic Acid in Endoscopic Transurethral Resections in Urology
Transurethral resection of the prostate (TURP) represents the gold standard in the operative management of benign prostatic hyperplasia (BPH) and the transurethral resection of bladder tumor (TURBT) is the first-line surgical…
- Trial name
- NCT02653261
- Testing
- Tranexamic Acid
- Where
- Tunisia
- Volunteers
- 131 people
- Sponsor
- University Tunis El Manar
Bladder Cancer
Enhanced Recovery After Surgery (ERAS) for Ambulatory TURBT
This is a single-center, randomized-controlled trial to investigate the effectiveness of an ERAS protocol compared to usual care in patients with bladder cancer undergoing ambulatory TURBT.
- Trial name
- NCT05905276
- Testing
- ERAS Protocol, Standard of Care
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Johns Hopkins University
Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Transurethral Resection of Bladder Tumor
Evaluation of the Role of Early Second Look TURBT in Management of High Risk Non Muscle Invasive Bladder Cancer
The aim is to evaluate the intraoperative, postoperative and pathologic findings of early second look TURBT and the factors affecting these findings to assess the value of early second TURBT in the management of high risk NMIBC.
- Trial name
- NCT07642102
- Testing
- early second look transurethral resection of bladder tumor
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Ain Shams University
Bladder Cancer
A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT)
This is a randomized, multicenter, two-arm, double-blind, placebo-controlled study of Qapzola in participants with low- to intermediate-risk non-muscle invasive bladder cancer (NMIBC), assessed according to the 2016 American…
- Trial name
- NCT03224182
- Testing
- Qapzola
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Bladder Cancer
Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)
The purpose of this study was to evaluate the 2-Year Recurrence Rate of bladder cancer in randomized patients with tumor histology Ta, G1-G2 who received TransUrethral Resection of Bladder Tumor (TURBT) plus apaziquone versus…
- Trial name
- NCT00461591
- Testing
- Apaziquone, TURBT
- Where
- 74 sites in United States
- Volunteers
- 802 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Bladder Cancer
S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00445601
- Testing
- gemcitabine hydrochloride
- Where
- 70 sites in United States
- Volunteers
- 406 people
- Sponsor
- SWOG Cancer Research Network
Bladder Cancer, Urothelial Carcinoma
A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
This global, randomized, controlled, open-label Phase 3 study was designed to assess the long-term efficacy and safety of UGN-102 (mitomycin) for intravesical solution with or without (±) transurethral resection of bladder tumors…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
- Trial name
- ATLAS (NCT04688931)
- Testing
- UGN-102, TURBT
- Where
- 139 sites in United States, Bulgaria and 8 more
- Volunteers
- 282 people
- Sponsor
- UroGen Pharma Ltd.
Carcinoma in Situ, Transitional Cell Carcinoma
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
This is a Phase 3b open-label, randomized, parallel-arm, multicenter study to evaluate the efficacy and safety of 10 monthly intravesical administrations of maintenance therapy with valrubicin following induction with valrubicin…
- Conditions
- Carcinoma in Situ, Transitional Cell Carcinoma, Non-muscle Invasive Bladder Cancer
- Trial name
- NCT01310803
- Testing
- VALSTAR - Maintenance Therapy, No Maintenance treatment ( Standard of Care)
- Where
- 6 sites in United States
- Volunteers
- 1 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company